Better survival after transcatheter aortic valve replacement by process improvements

Area of Science:

• Cardiology
• Healthcare Quality Improvement
• Interventional Cardiology

Background:

• Transcatheter aortic valve replacement (TAVR) is a critical procedure for aortic valve disease.
• Assessing the impact of quality improvement initiatives is crucial for patient outcomes.
• Mortality rates post-TAVR necessitate continuous evaluation and enhancement of care strategies.

Purpose of the Study:

• To evaluate the effectiveness of a novel quality improvement strategy on procedural, 30-day, and 1-year all-cause mortality in TAVR patients.
• To determine if the implemented interventions led to a significant reduction in mortality following TAVR.
• To analyze the influence of patient and procedural characteristics on the strategy's impact on mortality.

Main Methods:

• A retrospective analysis of 806 patients undergoing TAVR between 2013 and 2018 at a single Dutch center.
• Comparison of mortality outcomes between a pre-quality improvement strategy cohort (Jan 2013-Oct 2015) and a post-strategy cohort (Nov 2015-Dec 2018).
• Logistic regression analysis was employed to assess the impact of the quality improvement strategy, adjusting for patient and procedural factors.

Main Results:

• The quality improvement strategy was associated with a significant decrease in procedural mortality (4.4% to 1.3%), 30-day mortality (8.4% to 2.7%), and 1-year mortality (16.4% to 8.5%).
• Multivariate analysis confirmed that the strategy significantly reduced 30-day (OR 0.19) and 1-year (OR 0.38) all-cause mortality, even after accounting for patient characteristics.
• The study included 274 patients in the pre-strategy cohort and 532 patients in the post-strategy cohort.

Conclusions:

• Outcome-based quality improvement initiatives, driven by structural evaluation meetings, can effectively lower mortality rates after TAVR.
• The implemented strategy demonstrated a significant positive impact on reducing all-cause mortality at procedural, 30-day, and 1-year follow-up.
• Continuous assessment and refinement of quality improvement interventions are vital for enhancing patient survival post-TAVR.